Search Results for “EC” – Page 228 – media

OLYMVAX Trivalent Influenza Virus Cracking Vaccine (MDCK Cells) Clinical Trial Application Accepted

Recently, the State Drug Administration website announced that it agreed to accept OLYMVAX’s application for clinical trials of trivalent influenza virus lysate vaccine (MDCK cells), which is also the first cell-based trivalent influenza vaccine to be declared for clinical use in China. Influenza vaccination is an effective means of preventing influenza and reducing the burden of influenza-associated severe illness and death. Divided from the components of the vaccine and the types of preventive viruses, the influenza vaccines currently available in China include trivalent influenza vaccine and tetravalent influenza vaccine. Trivalent influenza vaccine mainly prevents H1N1 and H3N2 subtypes of Influenza A, as well as Influenza B Victoria lineage viruses, while tetravalent influenza vaccine is based on trivalent influenza vaccine, with added prevention against Influenza B Yamagata lineage viruses. OLYMVAX’s quadrivalent influenza virus lysate vaccine (MDCK cells) has been approved by the State Drug Administration for the issuance of the Notice ...
- Source: drugdu
- 121
- July 9, 2024
NeuroSense Therapeutics shares positive results of lead candidate in ALS

The neurodegenerative disease currently affects more than 200,000 people worldwide NeuroSense Therapeutics has announced positive mid-stage results of its lead drug candidate, PrimeC, in people living with amyotrophic lateral sclerosis (ALS). The phase 2b PARADIGM study has been evaluating PrimeC, a fixed-dose combination of two US Food and Drug Administration (FDA)-approved drugs, Bayer’s ciprofloxacin, a well-known antibiotic, and Pfizer’s Celebrex (celecoxib), a COX inhibitor used to treat inflammation, in 68 people living with the neurodegenerative disease in Canada, Italy and Israel. Affecting more than 200,000 people globally, ALS is a neurological disorder that affects the motor neurons, the nerve cells in the brain and the spinal cord that control voluntary muscle movement and breathing. Previously granted Orphan Drug Designation by the FDA and the European Medicines Agency, PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic ...
- Source: drugdu
- 77
- July 9, 2024
Study reveals mobile phone data can help map the spread of pathogens

Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide A study, published in Nature, has revealed a new way to map the spread and evolution of pathogens, as well as their response to vaccines and antibiotics, using anonymised mobile phone data, to help predict and prevent future outbreaks. The study involved researchers from the Wellcome Sanger Institute, the University of the Witwatersrand, the National Institute for Communicable Disease, South Africa and the University of Cambridge, as well as partners from the Global Pneumococcal Sequencing project. Infectious diseases, including tuberculosis, HIV and COVID-19, have multiple strains or variants that circulate simultaneously. The leading cause of pneumonia, meningitis and sepsis worldwide, the bacterium Streptococcus pneumoniae (pneumococcus) has over 100 types and 900 genetic strains globally. Researchers integrated genomic data from 6,910 pneumococcus samples collected in South Africa between 2000 and 2014 with anonymised human travel patterns collected by Meta2 using ...
- Source: drugdu
- 94
- July 9, 2024
New Highly-Sensitive Test to Help More Easily Diagnose B-Cell Lymphoma

B-cell lymphoma, a cancer primarily originating in the lymphatic system, represents about 85% of non-Hodgkin lymphoma (NHL) diagnoses. NHL ranks as the tenth most prevalent cancer globally, claiming over 250,000 lives annually. In its early stages, NHL can manifest with symptoms such as swollen lymph nodes, fever, fatigue, loss of appetite, or a red rash. These symptoms, however, can mimic the body’s typical response to infections, making a precise diagnosis crucial. symptoms of lymphoma can appear similar to the body’s normal reactive response to an infection. Now, a first-of-its-kind assay can offer diagnostic certainty for patients with suspected B-cell lymphoma. Roche (Basel, Switzerland) has introduced the first clinically approved, highly sensitive in-situ hybridization (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, available in regions accepting the CE Mark. This assay stands out as the first clinically approved ISH test designed to detect the entire range ...
- Source: drugdu
- 91
- July 8, 2024
Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy

By Don Tracy, Associate Editor Results of the Phase III CARTITUDE-4 study showed that treatment with Carvykti achieved a more significant improvement in overall survival (OS) compared to standard therapies. Results from the second interim analysis of the Phase III CARTITUDE-4 study, which evaluated Johnson & Johnson’s (J&J) Carvykti (ciltacabtagene autoleucel; cilta-cel) for patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy showed that the treatment achieved a statistically significant and clinically meaningful improvement in overall survival (OS) compared to standard therapies such as omalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 “Carvykti, a one-time infusion, is now the first cell therapy to significantly improve overall survival versus standard of care for patients with myeloma as early as second line,” said Jordan Schecter, MD, VP, disease area leader, multiple myeloma, Johnson & Johnson Innovative Medicine, in a press release. “As we continue to ...
- Source: drugdu
- 111
- July 8, 2024
FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701, a Treatment for Patients with ABCC6 Deficiency

By Don Tracy, Associate Editor The Fast Track designation for INZ-701 was based nonclinical pharmacology data and preliminary safety and efficacy data from the ongoing Phase I/II trial of INZ-701 in adults with ABCC6 Deficiency. The FDA has granted Fast Track Designation for Inozyme Pharma’s INZ-701, aimed to treat patients with ABCC6 Deficiency. According to the company, the Fast Track designation was based on preliminary safety and efficacy data from its ongoing Phase I/II trial of INZ-701 in adults with ABCC6 Deficiency, as well as nonclinical pharmacology data. Inozyme believes that INZ-701’s development process will benefit from more frequent engagement with the FDA and expedited regulatory review.1 “Through Fast Track designation, the FDA recognizes the potential of INZ-701 in ABCC6 Deficiency. We plan to work closely with the agency to establish an efficient path to approval. Receipt of Fast Track designation underscores our belief that INZ-701 could serve as an ...
- Source: drugdu
- 101
- July 8, 2024
EMA validates Philogen and Sun Pharma’s MAA for melanoma

The European Medicines Agency (EMA) has validated Philogen and Sun Pharmaceutical’s marketing authorisation application (MAA) for Nidlegy, a treatment for melanoma. Nidlegy is an investigational treatment for neoadjuvant (before surgical procedure) locally advanced fully resectable melanoma. The application, submitted on 4 June 2024, is based on data from the Phase III PIVOTAL study and a Phase II trial. The international, multicentre, randomised, comparator-controlled, parallel-group PIVOTAL trial assessed the efficacy and safety of Nidlegy as a neoadjuvant treatment in melanoma patients with locally advanced, fully resectable cutaneous, subcutaneous or nodal metastases accessible to intratumoural injection. A total of 256 patients were enrolled across 22 clinical centres in Italy, Germany, France and Poland. Results from the PIVOTAL trial showed that Nidlegy reduced the relapse or mortality risk by 41% versus the control arm, with a significant improvement in median recurrence-free survival and distant metastasis-free survival (DMFS). Nidlegy’s safety profile was characterised by ...
- Source: drugdu
- 107
- July 8, 2024
Pendopharm and Ascendis to distribute hypoparathyroidism treatment

Pharmascience unit Pendopharm has entered an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market. Pendopharm will be responsible for securing regulatory approval and overseeing the commercialisation of the product in the country. Neither companies has disclosed the financial terms of the deal. Ascendis Pharma executive vice-president and chief commercial officer Camilla Harder Hartvig stated: “We are delighted to partner with Pendopharm to bring TransCon PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism.” A parathyroid hormone (PTH) replacement therapy, TransCon PTH is aimed at treating chronic hypoparathyroidism, a rare endocrine disorder characterised by low or inadequate levels of PTH. The therapy has already secured approval in the European Union, the European Economic Area and Great Britain under the brand name YORVIPATH, specifically for adult patients. TransCon PTH ...
- Source: drugdu
- 79
- July 8, 2024
Hengrui Pharmaceuticals’ Innovative Drug HRS-9813 Tablets for Treatment of Idiopathic Pulmonary Fibrosis Approved for Clinical Trial

Recently, Hengrui Pharmaceuticals’ subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, which approved HRS-9813 tablets, a Class 1 new drug, to carry out clinical trials for idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease of unknown cause, which ultimately leads to hypoxemia, respiratory failure and even death.IPF was included in the first batch of China’s rare disease catalog in 2018, and in recent years, studies have shown that its incidence and prevalence are on the rise globally, and its prognosis is poor, and it is one of the diseases that researchers are currently working to overcome. Currently, there are limited drugs approved for the treatment of IPF at home and abroad, and there are still deficiencies in terms of safety and patient compliance.There is still a huge unmet ...
- Source: drugdu
- 94
- July 8, 2024
The Need for Contextualization and Cloud-based Integration

Data exchange lies at the heart of innovation. With the right data available, BioPharma companies can best implement advanced analytics tools for timely interventions in manufacturing deficiencies and optimize processes. By Harlan KnappBuilt-in data integrity is a bare minimum requirement in today’s BioPharmaceutical manufacturing. Good Manufacturing Practices (GMP) regulations of the Food and Drug Administration (FDA) highlight the importance of the accuracy and reliability of data across supply chains. Yet, the difficulty of achieving this milestone can still be underestimated by drug sponsors, especially when working with manufacturing partners. Although organizations are expected to demonstrate full governance of their data across the product lifecycle, their access to process data remains limited, which hinders early risk detection as well as the scalability of manufacturing. With agile manufacturing networks, novel therapeutic modalities such as mRNA vaccines and cell and gene therapies, the single-source manufacturing model using on-premise/siloed infrastructure can have an adverse ...
- Source: drugdu
- 116
- July 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.